|
시장보고서
상품코드
1983135
블라인드 루프 증후군(맹관증후군) 시장 : 유형별, 해부학적 부위별, 중증도별, 치료법별, 투여 경로별, 연령층별, 최종사용자별, 유통 채널별, 지역별Blind Loop Syndrome Market, By Type, By Anatomical Location, By Severity, By Treatment Modality, By Route of Administration, By Age Group, By End User, By Distribution Channel, By Geography |
||||||
블라인드 루프 증후군(맹관증후군) 시장은 2026년에 2억 4,280만 달러로 추정되며, 2033년까지 4억 8,841만 달러에 달할 것으로 예상됩니다. 2026년부터 2033년까지 CAGR 10.5%로 성장할 것으로 전망됩니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도: | 2025년 | 2026년 시장 규모: | 2억 4,280만 달러 |
| 과거 데이터 기간: | 2020-2024년 | 예측 기간: | 2026-2033년 |
| 2026년부터 2033년까지 예측 기간 CAGR: | 10.50% | 2033년 시장 규모 예측: | 4억 8,841만 달러 |
세계 블라인드 루프 증후군 시장은 광범위한 소화기 질환 치료 분야의 전문 분야로, 고립된 장의 일부에 비정상적인 박테리아가 과도하게 증식하는 복잡한 질환을 치료하는 시장입니다.
블라인드 루프 증후군은 소장의 일부가 폐쇄된 루프를 형성하여 세균이 과도하게 증식하는 정체 영역이 생겨 발생합니다. 이로 인해 흡수 장애, 영양 결핍 및 다양한 소화기 계통의 합병증을 유발할 수 있습니다. 이 질환은 수술, 해부학적 이상 또는 기저 소화기 질환으로 인해 발생할 수 있으며, 전 세계 의료진과 환자들에게 심각한 문제로 대두되고 있습니다.
이 시장에는 항생제 치료, 영양 보충제, 프로바이오틱스, 외과적 교정 시술 등 다양한 치료법이 포함됩니다. 이 증후군의 진단과 관리에 대한 의료진의 인식이 높아진 데다 진단 기술 및 치료법의 발전이 시장 확대를 견인하고 있습니다. 소화기 수술의 증가, 염증성 장질환의 유병률 증가, 소화기 질환에 취약한 고령 인구의 증가가 시장 성장에 기여하는 주요 요인으로 작용하고 있습니다.
또한, 의료 인프라의 개선, 진단 능력의 향상, 그리고 세계 의료비 증가는 시장 발전에 유리한 환경을 조성하고 있으며, 블라인드 루프 증후군 시장은 전문 소화기 치료 분야에서 중요한 틈새 시장으로 자리매김하고 있습니다.
시장 역학
세계 블라인드 루프 증후군 시장은 주로 몇 가지 상호 연관된 요인에 의해 주도되고 있으며, 이러한 요인들이 결합되어 시장의 성장과 확장을 촉진하고 있습니다. 위장 수술, 특히 비만 수술과 장 절제술의 보급 확대는 주요 성장 요인으로 작용하고 있습니다. 이러한 수술은 종종 블라인드 루프 형성을 유발하기 쉬운 해부학적 상태를 만들기 때문입니다. 크론병, 궤양성 대장염 등 염증성 장질환의 유병률 증가도 시장 수요를 더욱 확대시키고 있습니다. 이러한 질환은 종종 수술적 처치가 필요하고, 맹검루프 합병증을 유발할 수 있기 때문입니다.
소화기내과 전문의와 의료진 사이에서 이 증후군의 임상적 중요성에 대한 인식이 높아진 데다, 첨단 영상 진단 기술과 세균 배양법 등 진단 능력의 향상으로 조기 발견과 조기 치료 시작이 촉진되고 있습니다. 특히 각종 소화기 질환이나 수술에 취약한 고령 인구의 증가도 또 다른 중요한 성장 요인으로 작용하고 있습니다. 그러나 일차 진료 의사들 사이에서 이 증후군에 대한 인식이 제한적이어서 진단과 치료가 지연되는 등 시장 성장의 제약요인이 존재하고 있습니다. 이 증후군의 복잡한 특성은 종종 오진이나 인식의 지연을 초래하여 적시에 치료 개입을 방해합니다.
또한, 표준화된 치료 프로토콜의 부재와 임상 연구 데이터의 부족은 의료진이 최적의 치료 전략을 선택하는 데 어려움을 겪고 있습니다. 특히 특수 항생제나 건강보조식품에 소요되는 고가의 치료비는 신흥국의 시장 접근성을 제한할 수 있습니다. 그럼에도 불구하고, 표적 항생제 치료와 혁신적인 프로바이오틱스 제제를 포함한 새로운 치료 접근법에 대한 연구의 진전을 통해 큰 기회가 존재합니다. 개선된 진단 도구와 바이오마커의 개발은 큰 시장 잠재력을 가지고 있으며, 신흥 시장에서의 의료 투자 증가와 개인화된 의료 접근법에 대한 관심 증가는 블라인드 루프 증후군 관리의 시장 확대와 혁신에 유리한 조건을 조성하고 있습니다.
본 조사의 주요 특징
- 이 보고서는 세계 블라인드 루프 증후군 시장에 대한 상세한 분석을 제공하며, 2025년을 기준 연도, 예측 기간(2026-2033년)의 시장 규모와 연평균 성장률(CAGR)을 제시합니다.
- 이 보고서는 각 부문의 잠재적 수익 기회를 밝히고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
- 또한 시장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업의 경쟁 전략에 대한 중요한 인사이트도 제공합니다.
- 이 보고서에서는 회사 개요, 제품 포트폴리오, 주요 특징, 재무 성과 및 전략과 같은 매개 변수를 기반으로 세계 블라인드 루프 증후군 시장의 주요 업체를 프로파일링합니다.
- 이 보고서의 내용을 통해 기업의 마케팅 담당자와 경영진은 향후 제품 출시, 제품 업그레이드, 시장 확대 및 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있습니다.
- 이 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입자, 금융 분석가 등 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계 블라인드 루프 증후군 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 쉽게 내릴 수 있습니다.
목차
제1장 조사 목적과 가정
제2장 시장 범위
제3장 시장 역학, 규제 및 동향 분석
제4장 세계의 블라인드 루프 증후군 시장 : 유형별, 2021-2033년
제5장 세계의 블라인드 루프 증후군 시장 : 해부학적 부위별, 2021-2033년
제6장 세계의 블라인드 루프 증후군 시장 : 중증도별, 2021-2033년
제7장 세계의 블라인드 루프 증후군 시장 : 치료법별, 2021-2033년
제8장 세계의 블라인드 루프 증후군 시장 : 투여 경로별, 2021-2033년
제9장 세계의 블라인드 루프 증후군 시장 : 연령층별, 2021-2033년
제10장 세계의 블라인드 루프 증후군 시장 : 최종사용자별, 2021-2033년
제11장 세계의 블라인드 루프 증후군 시장 : 유통 채널별, 2021-2033년
제12장 세계의 블라인드 루프 증후군 시장 : 지역별, 2021-2033년
제13장 경쟁 구도
제14장 애널리스트의 추천
제15장 참고문헌 및 조사 방법
KSM 26.04.15Blind Loop Syndrome Market is estimated to be valued at USD 242.8 Mn in 2026 and is expected to reach USD 488.41 Mn by 2033, growing at a compound annual growth rate (CAGR) of 10.5% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 242.8 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 10.50% | 2033 Value Projection: | USD 488.41 Mn |
Global blind loop syndrome market represents a specialized segment within the broader gastrointestinal disorders therapeutic landscape, addressing a complex medical condition characterized by abnormal bacterial overgrowth in isolated intestinal segments.
Blind loop syndrome occurs when a portion of the small intestine forms a closed-end loop, creating stagnant areas where bacteria can proliferate excessively, leading to malabsorption, nutritional deficiencies, and various gastrointestinal complications. This condition can arise from surgical procedures, anatomical abnormalities, or underlying digestive disorders, making it a significant concern for healthcare providers and patients worldwide.
The market encompasses various therapeutic interventions including antibiotic treatments, nutritional supplements, probiotics, and surgical correction procedures. Growing awareness among healthcare professionals about the syndrome's diagnosis and management, coupled with advancing diagnostic technologies and treatment modalities, is driving market expansion. The increasing prevalence of gastrointestinal surgeries, rising incidence of inflammatory bowel diseases, and growing geriatric population susceptible to digestive disorders are key factors contributing to market growth.
Additionally, improved healthcare infrastructure, enhanced diagnostic capabilities, and increasing healthcare expenditure globally are creating favorable conditions for market development, positioning the blind loop syndrome market as an important niche within the specialized gastrointestinal therapeutics sector.
Market Dynamics
The global blind loop syndrome market is primarily driven by several interconnected factors that collectively propel market growth and expansion. The increasing prevalence of gastrointestinal surgeries, particularly bariatric procedures and bowel resections, serves as a primary growth driver as these surgical interventions often create anatomical conditions conducive to blind loop formation. Rising incidence of inflammatory bowel diseases, including Crohn's disease and ulcerative colitis, further amplifies market demand as these conditions frequently require surgical interventions that may result in blind loop complications.
Growing awareness among gastroenterologists and healthcare professionals about the syndrome's clinical significance, coupled with improved diagnostic capabilities including advanced imaging techniques and bacterial culture methods, is facilitating earlier detection and treatment initiation. The expanding geriatric population, particularly susceptible to various gastrointestinal disorders and surgical procedures, represents another significant growth driver. However, market growth faces notable restraints including limited awareness about the condition among primary care physicians, leading to delayed diagnosis and treatment. The complex nature of the syndrome often results in misdiagnosis or delayed recognition, hampering timely therapeutic intervention.
Additionally, the lack of standardized treatment protocols and limited clinical research data pose challenges for healthcare providers in selecting optimal treatment strategies. High treatment costs, particularly for specialized antibiotics and nutritional supplements, may limit market accessibility in emerging economies. Nevertheless, substantial opportunities exist through advancing research into novel therapeutic approaches, including targeted antibiotic therapies and innovative probiotic formulations. The development of improved diagnostic tools and biomarkers presents significant market potential, while increasing healthcare investments in emerging markets and growing focus on personalized medicine approaches create favorable conditions for market expansion and innovation in blind loop syndrome management.
Key Features of the Study
- This report provides in-depth analysis of the global blind loop syndrome market, and provides market size (USD Mn) and compound annual growth rate (CAGR%) for the forecast period (2026-2033), considering 2025 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global blind loop syndrome market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Takeda Pharmaceutical Company, Pfizer, GlaxoSmithKline, Novartis, AbbVie, Sanofi, Johnson & Johnson, Merck & Co., Bayer, AstraZeneca, Roche, BristolMyers Squibb, Eli Lilly and Company, Amgen, and Ferring Pharmaceuticals
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global blind loop syndrome market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global blind loop syndrome market
Market Segmentation
- Type Insights (Revenue, USD Mn, 2021 - 2033)
- Post-surgical blind loop syndrome
- Structural (non-surgical) causes
- Motility-related causes
- Anatomical Location Insights (Revenue, USD Mn, 2021 - 2033)
- Duodenal/jejunal loop involvement
- Jejunoileal segment involvement
- Ileocecal region involvement
- Others (Length/extent of affected segment, etc.)
- Severity Insights (Revenue, USD Mn, 2021 - 2033)
- Mild
- Moderate
- Severe/complicated
- Treatment Modality Insights (Revenue, USD Mn, 2021 - 2033)
- Pharmacologic therapy
- Antibiotics
- Adjunct GI therapies
- Microbiome-directed adjuncts
- Nutritional & deficiency correction
- Vitamin replacement
- Macronutrient support
- Medical nutrition
- Route of Administration Insights (Revenue, USD Mn, 2021 - 2033)
- Oral
- Injectable
- Enteral tube feeding
- Age Group Insights (Revenue, USD Mn, 2021 - 2033)
- Pediatric
- Adults
- Geriatric
- End User Insights (Revenue, USD Mn, 2021 - 2033)
- Hospitals
- Outpatient Specialty Clinics
- Ambulatory Diagnostic Centers
- Homecare Settings
- Others (Academic and Research Institutes, etc.)
- Distribution Channel Insights (Revenue, USD Mn, 2021 - 2033)
- Hospital pharmacy
- Retail pharmacy
- Online pharmacy
- Regional Insights (Revenue, USD Mn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Takeda Pharmaceutical Company
- Pfizer
- GlaxoSmithKline
- Novartis
- AbbVie
- Sanofi
- Johnson & Johnson
- Merck & Co.
- Bayer
- AstraZeneca
- Roche
- BristolMyers Squibb
- Eli Lilly and Company
- Amgen
- Ferring Pharmaceuticals
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Blind Loop Syndrome Market, By Type
- Global Blind Loop Syndrome Market, By Anatomical Location
- Global Blind Loop Syndrome Market, By Severity
- Global Blind Loop Syndrome Market, By Treatment Modality
- Global Blind Loop Syndrome Market, By Route of Administration
- Global Blind Loop Syndrome Market, By Age Group
- Global Blind Loop Syndrome Market, By End User
- Global Blind Loop Syndrome Market, By Distribution Channel
- Global Blind Loop Syndrome Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Market Opportunities
- Regulatory Scenario
- Key Developments
- Industry Trends
4. Global Blind Loop Syndrome Market, By Type, 2021-2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Post-surgical blind loop syndrome
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Structural (non-surgical) causes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Motility-related causes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
5. Global Blind Loop Syndrome Market, By Anatomical Location, 2021-2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Duodenal/jejunal loop involvement
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Jejunoileal segment involvement
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Ileocecal region involvement
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Others (Length/extent of affected segment, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
6. Global Blind Loop Syndrome Market, By Severity, 2021-2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Mild
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Moderate
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Severe/complicated
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
7. Global Blind Loop Syndrome Market, By Treatment Modality, 2021-2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Pharmacologic therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Antibiotics
- Adjunct GI therapies
- Microbiome-directed adjuncts
- Nutritional & deficiency correction
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Vitamin replacement
- Macronutrient support
- Medical nutrition
8. Global Blind Loop Syndrome Market, By Route of Administration, 2021-2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Injectable
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Enteral tube feeding
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
9. Global Blind Loop Syndrome Market, By Age Group, 2021-2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Pediatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Adults
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Geriatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
10. Global Blind Loop Syndrome Market, By End User, 2021-2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Outpatient Specialty Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Ambulatory Diagnostic Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Homecare Settings
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Others (Academic and Research Institutes, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
11. Global Blind Loop Syndrome Market, By Distribution Channel, 2021-2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospital pharmacy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Retail pharmacy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Online pharmacy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
12. Global Blind Loop Syndrome Market, By Region, 2021 - 2033, Value (USD Mn)
- Introduction
- Market Share (%) Analysis, 2026, 2029 & 2033, Value (USD Mn)
- Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Mn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Anatomical Location, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Severity, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Treatment Modality, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Anatomical Location, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Severity, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Treatment Modality, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Anatomical Location, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Severity, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Treatment Modality, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Anatomical Location, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Severity, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Treatment Modality, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Anatomical Location, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Severity, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Treatment Modality, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Anatomical Location, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Severity, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Treatment Modality, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Mn)
- South Africa
- North Africa
- Central Africa
13. Competitive Landscape
- Takeda Pharmaceutical Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Pfizer
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- GlaxoSmithKline
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Novartis
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AbbVie
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sanofi
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Johnson & Johnson
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Merck & Co.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bayer
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AstraZeneca
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Roche
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bristola€'Myers Squibb
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Eli Lilly and Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Amgen
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Ferring Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
14. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
15. References and Research Methodology
- References
- Research Methodology
- About us
